Disruption of the Muscle–Brain Axis in Ageing: Role of Myokines in Sarcopenia and Neurodegeneration
- 1Health Sciences Department, School of Medicine, Universidad Técnica Particular de Loja, Loja 1101608, Ecuador
- 2Allied Health Department, School of Allied Health, Eastwick College, Ramsey, NJ 07446, USA
Abstract
This narrative review analyzes how myokines act as key links in communication between skeletal muscle and the brain, focusing on the impact of aging on this axis. Although the current literature links defects in this signaling pathway to sarcopenia, neurodegeneration, and cognitive decline, we still do not know exactly what role each molecule plays individually. Among the main gaps in our understanding are questions about how these substances are transported to the nervous system, what their specific receptors are, and what cause-and-effect relationship actually exists between losing muscle mass and developing neurological problems. In fact, in humans, it remains unclear whether myokines actually reach the brain in truly effective concentrations or whether their benefits are due more to peripheral metabolic, vascular, and inflammatory changes. Today, most of the mechanistic evidence comes from animal and cellular models, while observational studies predominate in humans. This is further complicated by uncertainties regarding the actual origin of these proteins in tissues, their passage through the blood–brain barrier, and their measurement in the blood, making it difficult to determine whether these proteins act as causes, consequences, or simply compensatory responses to aging and disease. On the other hand, although exercise remains the most robust tool for maintaining muscle health and protecting cognitive function, it is still unclear whether we could replicate those same benefits by isolating and stimulating specific myokines. The major challenge for the future is to develop human studies that combine standardized biomarkers with long-term monitoring of muscle function, cognition, and brain structure. Only then will we know whether this fascinating muscle–brain axis can move beyond being a promising hypothesis to become a real therapeutic target.
Related
- A blood test-derived skeletal muscle index combined with handgrip strength identifies a sarcopenia-related high-risk phenotype in non–dialysis-dependent chronic kidney disease
- Pre-diagnostic low muscle mass and sarcopenia associated with subsequent cancer in Chinese adults: a longitudinal CHARLS study
- Sarcopenia and Muscle Dysfunction in Older Adults with Burn Injuries: An Integrated Clinical Perspective
- Near infrared spectroscopy during non-ischaemic handgrip exercise reveals divergent muscle oxygenation signatures in mitochondrial disease and sarcopenia
- GLP-1-Based Pharmacotherapies and Skeletal Muscle Health in Obesity: A Narrative Review of Body Composition, Muscle Function, and Sarcopenia-Related Outcomes
BibTeX
@article{molina2026disruption,
title = {{Disruption of the Muscle–Brain Axis in Ageing: Role of Myokines in Sarcopenia and Neurodegeneration}},
author = {Víctor Agustín Morales Molina and Cecibel Nicole Ludeña Salinas and Celina Andrade Vásquez and Andri Matos and Diego Aldeán Riofrío},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15201910},
url = {https://www.mdpi.com/2073-4409/15/20/1910},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Disruption of the Muscle–Brain Axis in Ageing: Role of Myokines in Sarcopenia and Neurodegeneration
AU - Víctor Agustín Morales Molina
AU - Cecibel Nicole Ludeña Salinas
AU - Celina Andrade Vásquez
AU - Andri Matos
AU - Diego Aldeán Riofrío
PY - 2026
DA - 2026/10/20
JO - Cells
DO - 10.3390/cells15201910
UR - https://www.mdpi.com/2073-4409/15/20/1910
AB - This narrative review analyzes how myokines act as key links in communication between skeletal muscle and the brain, focusing on the impact of aging on this axis. Although the current literature links defects in this signaling pathway to sarcopenia, neurodegeneration, and cognitive decline, we still do not know exactly what role each molecule plays individually. Among the main gaps in our understanding are questions about how these substances are transported to the nervous system, what their specific receptors are, and what cause-and-effect relationship actually exists between losing muscle mass and developing neurological problems. In fact, in humans, it remains unclear whether myokines actually reach the brain in truly effective concentrations or whether their benefits are due more to peripheral metabolic, vascular, and inflammatory changes. Today, most of the mechanistic evidence comes from animal and cellular models, while observational studies predominate in humans. This is further complicated by uncertainties regarding the actual origin of these proteins in tissues, their passage through the blood–brain barrier, and their measurement in the blood, making it difficult to determine whether these proteins act as causes, consequences, or simply compensatory responses to aging and disease. On the other hand, although exercise remains the most robust tool for maintaining muscle health and protecting cognitive function, it is still unclear whether we could replicate those same benefits by isolating and stimulating specific myokines. The major challenge for the future is to develop human studies that combine standardized biomarkers with long-term monitoring of muscle function, cognition, and brain structure. Only then will we know whether this fascinating muscle–brain axis can move beyond being a promising hypothesis to become a real therapeutic target.
SN - 2073-4409
ER -